Sometimes, when something seems too good to be true, it is.
An example: this story about an expensive (up to $12,000 for the full treatment), newly-approved medical device to treat depression that involves magnets pulsing repetitively that was published in USA Today last week.
Though the treatment, called transcranial magnetic stimulation, may help some subset of depressed patients and is now covered by Medicare when other therapies have failed, the expert medical news analysts over at HealthNewsReview.org explain why the USA Today report paints an overly rosy picture of the treatment’s potential effectiveness.
Gary Schwitzer and colleague Harold DeMonaco write that “the story did not provide any semblance of balance in its reporting of the device.” Here’s a bit more from their far-reaching critique:
The story describes a single patient anecdote and does provide us with some information about the NIMH sponsored clinical trial: “Both Cochran and West cite high patient response rates. A clinical trial funded by the National Institutes of Health revealed a “significant effect of treatment” when patients received TMS treatment. It compared outcomes of patients who actually received the magnetic pulses against patients in a “sham” group, who sat down in the treatment chair for fake sessions.”
Here is what the lead author of the NIMH funded study said about the results performed in 190 patients with depression who failed standard drug therapy::
Thirteen (14 percent) of 92 patients who received the active treatment achieved remission, compared to 5 (about 5 percent) of 98 patients who received the simulation treatment.
“…the overall number of remitters and responders was less than one would like with a treatment that requires daily intervention for three weeks or more, even with a benign side effect profile.”
Hardly the results suggested by the story… Continue reading